MIAMI, FL / ACCESSWIRE / April 20, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company") a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries ("TBIs") is pleased to announce that Chenfeng Ke, Assistant Professor of Chemistry at Dartmouth College has joined its Scientific Advisory Board. Professor Ke and his group focus on syntheses and applications of polymeric materials for storage/separation and 3D printing applications. The research scheme, which the Company believes to be groundbreaking, overlaps organic synthesis, crystal engineering, polymer synthesis, materials characterization, and 3D printing, with an emphasis on the design of polymeric materials that are noncovalently assembled.
The Company has been conducting research with Professor Ke to develop innovative 3D printable, biocompatible advanced materials as a component of its stem cells TBI treatment and is negotiating with Dartmouth for a worldwide, exclusive license agreement for the intellectual property related to 3D printable materials in the field of human and animal health.
Earlier this month, the Company's co-founders and Head of Research and Development met with the heads of various departments at Dartmouth and discussed various matters concerning their collaborative relationship.
Ido Merfeld, co-Founder, President and Head of Product, remarked "Professor Ke's expertise in syntheses and applications of polymeric 3D printable materials will greatly complement our Scientific Advisory Board, and is in keeping with our multi-disciplinary research approach to address the unmet medical need of TBI. I have worked with Professor Ke for the last year and consider him to be a visionary in his field."
Jonah Meer co-founder and Chief Executive Officer, added, "We are excited with the results of our preliminary studies and are heartened with the reception we received from the various departments at Dartmouth. We are looking to deepen our relationship with Dartmouth--one of the world's greatest academic institutions."
Stated Professor Ke, "I am impressed at the research being done by Qrons regarding TBI as well as the integration of smart materials as part of their solution. As such, I am honored to have been asked and am excited to join their Scientific Advisory Board."
About Qrons Inc.
Headquartered in Miami, Florida, the Company is a publicly traded preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology could potentially treat a wide range of neurodegenerative diseases. The Company's treatment integrates proprietary, engineered mesenchymal stem cells 3D printable scaffolding, smart materials and a novel delivery system. The Company entered into a license and research funding agreement ("License Agreement") with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company is also conducting a research study with Professor Chenfeng Ke of the Chemistry Department at Dartmouth College aiming to develop innovative 3D printable, biocompatible advanced materials and stem cell delivery techniques to treat TBI. The Company is negotiating, a worldwide, royalty‑bearing, exclusive license for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.
Safe Harbor Statement
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning our future product development plans, other statements regarding future research, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual operations, results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; successful development of clinical studies for any product we may develop, U.S. Food and Drug Administration clearance for any products developed, manufacturing of a commercially-viable version of our system and demonstration of safety and effectiveness sufficient to generate commercial orders by customers for any product we may develop. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
INVESTOR AND MEDIA CONTACT
Qrons Inc.
Mr. Jonah Meer
E: [email protected]
P: 786-620-2140
SOURCE: Qrons Inc.